Peter Greenleaf Insider Trading $SCMP Sucampo Pharmaceuticals, Inc.
Get free email notifications about insider trading for Peter Greenleaf.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Peter Greenleaf. Peter Greenleaf is Senior VP, Sales & Marketing in MEDIMMUNE INC /DE ($MEDI) and SVP, Sales & Marketing in MEDIMMUNE INC /DE ($MEDI) and SVP, Sales and Marketing in MEDIMMUNE INC /DE ($MEDI) and Director in ANTARES PHARMA, INC. ($ATRS) and Director in BIODELIVERY SCIENCES INTERNATIONAL INC ($BDSI) and Director in Mast Therapeutics, Inc. ($MSTX) and CEO in Sucampo Pharmaceuticals, Inc. ($SCMP) and Chief Executive Officer in Sucampo Pharmaceuticals, Inc. ($SCMP) and Director in EYEGATE PHARMACEUTICALS INC ($EYEG) and Director in Mirna Therapeutics, Inc. ($MIRN) and in Cerecor Inc. ($CERC) and Chief Executive Officer in Cerecor Inc. ($CERC) and Director in Cerecor Inc. ($CERC) and Chief Executive Officer in Aurinia Pharmaceuticals Inc. ($AUPH).
Peter Greenleaf in Sucampo Pharmaceuticals, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Peter Greenleaf: CEO, Chief Executive Officer
Holdings: 4,792 shares
Current Value: $54,389
Latest Transaction: Jan 04 2018
$SCMP Market Capitalization: $496.69M
$SCMP Previous Close: $11.35
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Peter Greenleaf in Sucampo Pharmaceuticals, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ATRS, AUPH, BDSI, CERC, EYEG, MEDI, SVRA, SCMP, SYBX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 04 2018 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.10 | 171 | 1,556 | 4,792 | 4.6 K to 4.8 K (+3.70 %) |
| Oct 05 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Grant | A | 9.10 | 659 | 5,997 | 4,621 | 4 K to 4.6 K (+16.63 %) |
| Jul 07 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Grant | A | 8.93 | 673 | 6,010 | 3,962 | 3.3 K to 4 K (+20.46 %) |
| May 10 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Grant | A | 9.35 | 641 | 5,993 | 3,289 | 2.6 K to 3.3 K (+24.21 %) |
| Mar 08 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 11.85 | 237,000 | 2,808,450 | 1,667,000 | |
| Mar 08 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jan 06 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 10.46 | 135 | 1,412 | 2,648 | 2.5 K to 2.6 K (+5.37 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Option Exercise | M | 6.75 | 82,459 | 556,598 | 1,430,000 | |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Option Exercise | M | 6.75 | 117,541 | 793,402 | 1,512,459 | |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Sell | S | 16.75 | 82,459 | 1,381,188 | 2,513 | 85 K to 2.5 K (-97.04 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Buy | M | 6.75 | 82,459 | 556,598 | 84,972 | 2.5 K to 85 K (+3,281.30 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Sell | S | 16.91 | 117,541 | 1,987,618 | 2,513 | 120.1 K to 2.5 K (-97.91 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Buy | M | 6.75 | 117,541 | 793,402 | 120,054 | 2.5 K to 120.1 K (+4,677.32 %) |
| Oct 21 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.38 | 640 | 6,003 | 2,513 | 1.9 K to 2.5 K (+34.17 %) |
| Jul 18 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.32 | 751 | 6,999 | 1,873 | 1.1 K to 1.9 K (+66.93 %) |
| Jun 16 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.29 | 646 | 6,001 | 1,122 | 476 to 1.1 K (+135.71 %) |
| Mar 04 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 13.80 | 420,000 | 5,796,000 | 1,630,000 | |
| Mar 04 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 14.70 | 476 | 6,997 | 476 | 0 to 476 |
| Mar 13 2015 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 14.82 | 210,000 | 3,112,200 | 1,210,000 |
Page: 1